Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Larimar Therapeutics (LRMR) reported Q3 2024 financial results with a net loss of $15.5 million ($0.24 per share). The company maintains a strong balance sheet with $203.7 million in cash and equivalents, projecting runway into 2026. Their lead program, nomlabofusp for Friedreich's ataxia, continues advancement with key upcoming milestones including: a program update in mid-December 2024, initiation of PK run-in study in adolescents by year-end, planned global confirmatory study mid-2025, and targeted BLA submission in 2H 2025. The company recently received ILAP designation from MHRA to accelerate market access in the UK.
Larimar Therapeutics (LRMR) ha riportato i risultati finanziari del terzo trimestre 2024, con una perdita netta di 15,5 milioni di dollari (0,24 dollari per azione). L'azienda mantiene un solido bilancio con 203,7 milioni di dollari in contante e equivalenti, prevedendo di arrivare fino al 2026. Il loro programma principale, nomlabofusp per l'atassia di Friedreich, continua ad avanzare con importanti tappe imminenti, tra cui: un aggiornamento del programma a metà dicembre 2024, l'avvio di uno studio PK in adolescenza entro la fine dell'anno, uno studio globale di conferma previsto per metà 2025 e la presentazione mirata della BLA nella seconda metà del 2025. L'azienda ha recentemente ricevuto la designazione ILAP dalla MHRA per accelerare l'accesso al mercato nel Regno Unito.
Larimar Therapeutics (LRMR) informó los resultados financieros del tercer trimestre de 2024, con una pérdida neta de 15,5 millones de dólares (0,24 dólares por acción). La compañía mantiene un sólido balance con 203,7 millones de dólares en efectivo y equivalentes, proyectando continuidad hasta 2026. Su principal programa, nomlabofusp para la ataxia de Friedreich, sigue avanzando con hitos clave que se acercan, incluyendo: una actualización del programa a mediados de diciembre de 2024, el inicio de un estudio de PK en adolescentes para finales de año, un estudio de confirmación global planeado para mediados de 2025 y la presentación de la BLA programada para la segunda mitad de 2025. La compañía recibió recientemente la designación ILAP de la MHRA para acelerar el acceso al mercado en el Reino Unido.
라리마르 테라퓨틱스 (LRMR)는 2024년 3분기 재무 결과를 발표했으며, 순손실은 1,550만 달러(주당 0.24달러)입니다. 회사는 2억 3천7백만 달러의 현금 및 현금성 자산을 보유하고 있어 2026년까지의 자금 운용을 계획하고 있습니다. 그들의 주요 프로그램인 프리드리히의 운동실조를 위한 노믹라보푸스는 주요 예정 이정표와 함께 계속 진행되고 있으며, 이에는 2024년 12월 중순 프로그램 업데이트, 연말까지 청소년을 대상으로 하는 PK 연구 시작, 2025년 중반 예정된 글로벌 확인 연구, 2025년 하반기 목표 BLA 제출이 포함됩니다. 회사는 최근 MHRA로부터 영국 내 시장 접근을 가속화하기 위한 ILAP 지정을 받았습니다.
Larimar Therapeutics (LRMR) a annoncé ses résultats financiers pour le troisième trimestre 2024, avec une perte nette de 15,5 millions de dollars (0,24 dollar par action). La société maintient un bilan solide avec 203,7 millions de dollars en liquidités et équivalents, prévoyant un financement jusqu'en 2026. Leur programme principal, nomlabofusp pour l'ataxie de Friedreich, continue d'avancer avec des jalons clés à venir, notamment : une mise à jour du programme à la mi-décembre 2024, le lancement d'une étude PK chez des adolescents d'ici la fin de l'année, une étude de confirmation mondiale prévue pour mi-2025 et une soumission BLA ciblée au second semestre 2025. La société a récemment reçu la désignation ILAP de la MHRA pour accélérer l'accès au marché au Royaume-Uni.
Larimar Therapeutics (LRMR) hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Nettverlust von 15,5 Millionen Dollar (0,24 Dollar pro Aktie). Das Unternehmen verfügt über eine solide Bilanz mit 203,7 Millionen Dollar in bar und liquiden Mitteln und plant, bis 2026 aktiv zu bleiben. Ihr Hauptprogramm, nomlabofusp für die Friedreich-Ataxie, macht weiterhin Fortschritte mit anstehenden wichtigen Meilensteinen, darunter: ein Programm-Update Mitte Dezember 2024, den Start einer PK-Studie bei Jugendlichen bis Ende des Jahres, eine geplante globale Bestätigungsstudie für Mitte 2025 und die angestrebte BLA-Einreichung im zweiten Halbjahr 2025. Das Unternehmen hat kürzlich von der MHRA die ILAP-Designierung erhalten, um den Marktzugang im Vereinigten Königreich zu beschleunigen.
- Strong cash position of $203.7M with runway into 2026
- ILAP designation received from MHRA for accelerated UK market access
- Multiple regulatory designations secured (Orphan Drug, Fast Track, PRIME)
- On track for BLA submission in 2H 2025
- Increased net loss to $15.5M in Q3 2024 vs $9.1M in Q3 2023
- R&D expenses increased to $13.9M from $6.6M YoY
- G&A expenses increased to $4.3M from $3.8M YoY
Insights
The Q3 2024 results reveal a strong financial position with
The
The development program for nomlabofusp is hitting critical milestones in Friedreich's ataxia treatment. The upcoming December update on safety, PK and frataxin data from patients receiving 25mg daily doses will be important for validating the therapy's potential. The planned initiation of pediatric studies and regulatory progress, including ILAP designation and START program participation, strengthen the pathway to commercialization.
The comprehensive regulatory strategy, including orphan drug designations in US/EU and Fast Track status, positions nomlabofusp favorably for accelerated approval. The expansion into adolescent populations through the PK run-in study demonstrates a strategic approach to broadening the therapeutic application while gathering essential safety data.
- Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) study
- Initiation of PK run-in study in adolescents on track by year-end 2024
- Initiation of global confirmatory/registration study planned mid-2025
- Biologics License Application (BLA) submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval
- Strong balance sheet of
$203.7 million cash, cash equivalents and marketable securities as of September 30, 2024, with projected cash runway into 2026
BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2024 operating and financial results.
“Our nomlabofusp program continues to advance, with the potential to be the first frataxin protein replacement therapy for patients with FA. All sites are activated with ongoing enrollment in our OLE study evaluating the long-term safety, PK and frataxin levels in patients with FA following daily subcutaneous administration. In mid-December, we plan to provide a development program update that will include available safety, PK, and frataxin data from patients receiving 25 mg of nomlabofusp daily for up to 180 days in our OLE study. We expect to also provide an update on enrollment,” said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar. “In November, we look forward to presenting at the International Congress for Ataxia Research (ICAR) meeting new data on results from our completed dose exploration study including exploratory gene and lipid expression results following nomlabofusp treatment. In addition, we will also be presenting two posters with data from patients participating in our Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies and Phase 2 dose exploration study. One poster will provide patient data on baseline disease characteristics and baseline tissue frataxin levels, and the other will present the relationship between dose, PK and tissue frataxin levels using modeling and simulation. We remain on track to initiate a PK run-in study in adolescent patients with FA in the fourth quarter of this year which is the first step towards evaluating nomlabofusp treatment in pediatric patients.”
Dr. Ben-Maimon continued, “On the regulatory front, we were pleased to recently receive Innovative Licensing and Access Pathway (ILAP) designation from the Medicines and Healthcare Products Regulatory Agency (MHRA) which aims to facilitate patient access by accelerating time to market in the U.K. We also held our first meetings with the Food and Drug Administration (FDA) as part of the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program and appreciate the dialogue and interaction designed to help advance our development program. In parallel, we began work to further understand the continued areas of unmet need in the FA therapeutic landscape from the perspective of physicians, payers, and most importantly, patients. We will use this information to develop our commercial approach and to refine our market entry strategy. Finally, we continue scaling up our manufacturing efforts and collecting required data to support a potential accelerated approval path. Our targeted BLA submission remains on track for the second half of 2025.”
Recent Highlights
- Today, Larimar announced that it will provide a nomlabofusp development program update in mid-December 2024 that will include available safety, PK and frataxin data, as well as available clinical outcomes observations from patients currently receiving a daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the OLE study. An update on enrollment in the OLE study will also be provided.
- Larimar recently received ILAP designation from the MHRA for nomlabofusp for the treatment of adults and children with FA. ILAP aims to facilitate patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with U.K. regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (EU), Fast Track and Rare Pediatric Disease designations in the U.S., PRIME designation in the EU, and selected to be in the START pilot program by the FDA.
- Larimar is on track to initiate by year-end a PK run-in study in an initial cohort of 12-15 adolescents (12 to 17 years of age) with FA. Initiation of a second cohort of 12-15 children (2 to 11 years of age) is planned to follow next year. Study participants will be randomized 2:1 to receive either nomlabofusp or placebo daily. Following assessment of safety and exposure data of each cohort in the PK run-in study, participants will be eligible to screen for the OLE study.
- Larimar is on track for a planned initiation of a global confirmatory/registration study planned mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and Australia. Larimar continues to target BLA submission for the second half of 2025 to support accelerated approval.
- In September 2024, Larimar announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the ICAR meeting being held November 12-15, 2024, in London, U.K.
Third Quarter 2024 Financial Results
As of September 30, 2024, the Company had cash, cash equivalents and marketable securities totaling
Third quarter of 2024 compared to the third quarter of 2023
The Company reported a net loss for the third quarter of 2024 of
Research and development expenses for the third quarter of 2024 were
General and administrative expenses were
Nine months ended September 30, 2024 compared to the nine months ended September 30, 2023
The Company reported a net loss for the 9-month period ending September 30, 2024 of
Research and development expenses for the 9-month period ending September 30, 2024 were
General and administrative expenses for the 9-month period ending September 30, 2024 were
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plan and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
| Larimar Therapeutics, Inc. | ||||||||
| Condensed Consolidated Balance Sheet | ||||||||
| (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 35,067 | $ | 26,749 | ||||
| Short-term marketable securities | 168,640 | 60,041 | ||||||
| Prepaid expenses and other current assets | 9,549 | 3,385 | ||||||
| Total current assets | 213,256 | 90,175 | ||||||
| Property and equipment, net | 779 | 684 | ||||||
| Operating lease right-of-use assets | 3,026 | 3,078 | ||||||
| Restricted cash | 1,339 | 1,339 | ||||||
| Other assets | 621 | 659 | ||||||
| Total assets | $ | 219,021 | $ | 95,935 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,686 | $ | 1,283 | ||||
| Accrued expenses | 13,573 | 7,386 | ||||||
| Operating lease liabilities, current | 1,026 | 837 | ||||||
| Total current liabilities | 16,285 | 9,506 | ||||||
| Operating lease liabilities | 4,336 | 4,709 | ||||||
| Total liabilities | 20,621 | 14,215 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock; | — | — | ||||||
| Common stock, | 64 | 43 | ||||||
| Additional paid-in capital | 438,312 | 270,150 | ||||||
| Accumulated deficit | (240,334 | ) | (188,554 | ) | ||||
| Accumulated other comprehensive gain | 358 | 81 | ||||||
| Total stockholders’ equity | 198,400 | 81,720 | ||||||
| Total liabilities and stockholders’ equity | $ | 219,021 | $ | 95,935 | ||||
| Larimar Therapeutics, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 13,919 | $ | 6,585 | $ | 46,540 | $ | 17,022 | ||||||||
| General and administrative | 4,345 | 3,754 | 13,057 | 10,574 | ||||||||||||
| Total operating expenses | 18,264 | 10,339 | 59,597 | 27,596 | ||||||||||||
| Loss from operations | (18,264 | ) | (10,339 | ) | (59,597 | ) | (27,596 | ) | ||||||||
| Other income, net | 2,765 | 1,275 | 7,817 | 3,640 | ||||||||||||
| Net loss | $ | (15,499 | ) | $ | (9,064 | ) | $ | (51,780 | ) | $ | (23,956 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.24 | ) | $ | (0.21 | ) | $ | (0.86 | ) | $ | (0.55 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 63,806,158 | 43,903,738 | 60,399,697 | 43,899,670 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (15,499 | ) | $ | (9,064 | ) | $ | (51,780 | ) | $ | (23,956 | ) | ||||
| Other comprehensive gain (loss): | ||||||||||||||||
| Unrealized gain (loss) on marketable securities | 508 | (5 | ) | 277 | 38 | |||||||||||
| Total other comprehensive gain (loss) | 508 | (5 | ) | 277 | 38 | |||||||||||
| Total comprehensive loss | $ | (14,991 | ) | $ | (9,069 | ) | $ | (51,503 | ) | $ | (23,918 | ) | ||||
FAQ
What was Larimar Therapeutics (LRMR) Q3 2024 net loss?
When is LRMR planning to submit BLA for nomlabofusp?
What is LRMR's current cash position and runway?
When will LRMR provide the next nomlabofusp program update?
